TRIAZOLAM TABLETS 0.25MG 0.25 MG
TRIAZOLAM : 0.25 MG · DIN 02230025 · PREMPHARM INC
Health Canada status: CANCELLED POST MARKET
What is TRIAZOLAM TABLETS 0.25MG?
TRIAZOLAM TABLETS 0.25MG 0.25 MG contains TRIAZOLAM : 0.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02230025, held by PREMPHARM INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 05-Aug-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02230025 |
|---|---|
| Brand name | TRIAZOLAM TABLETS 0.25MG |
| Generic / active ingredient | TRIAZOLAM : 0.25 MG |
| Manufacturer | PREMPHARM INC |
| Strength | 0.25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05CD05 TRIAZOLAM |
| AHFS class | 28:24.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 05-Aug-2005 |
| Original market date | 1997-04-30 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N05CD05 TRIAZOLAM. 1 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TRIAZOLAM | 0.25 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00808571 |
| ALTI-TRIAZOLAM TAB 0.125MG | .125 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 00614351 |
| ALTI-TRIAZOLAM TAB 0.25MG | .25 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 00614378 |
| HALCION | 0.125 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00512559 |
| HALCION | 0.25 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00443158 |
| MYLAN-TRIAZOLAM | 0.125 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 01995227 |
| MYLAN-TRIAZOLAM | 0.25 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 01913506 |
| NOVO-TRIOLAM TAB 0.125MG | .125 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00872423 |
| NOVO-TRIOLAM TAB 0.25MG | .25 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00872431 |
| PENTA-TRIAZOLAM TABLETS | .125 MG | TABLET | PENTAPHARM LTD. | CANCELLED (UNRETURNED ANNUAL) | DIN 02232553 |
Who else supplies TRIAZOLAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRIAZOLAM appears in 11 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.